Supernus Pharmaceuticals Inc

Research Supernus Pharmaceuticals Inc (SUPN) on Bullrun: market cap USD 1.52B, dividend yield 29.4%. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is USD 1.52B; dividend yield is 29.4%.

Peer valuation comparison

Latest dividend yield is 29.44% versus a Healthcare sector median of 2.39% (1131.8% above).

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025USD 718.95M-USD 38.60MUSD 45.99M89.6%-0.68USD 128.45MUSD 40.98MUSD 1.06B
FY2024USD 661.82MUSD 73.90MUSD 171.23M88.2%1.32USD 69.33MUSD 34.27MUSD 1.04B
FY2023USD 607.52MUSD 1.30MUSD 110.53M86.2%0.02USD 75.05MUSD 41.53MUSD 921.52M
FY2022USD 667.24MUSD 60.70MUSD 116.41M86.9%1.04USD 93.12MUSD 444.76MUSD 886.20M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-11-06USD 1.52Bn/a31.1%8.13
20252025-12-31USD 2.86Bn/an/an/a
20242024-12-31USD 2.02B27.4n/an/a
20232023-12-29USD 1.58B74.2n/an/a
20222022-12-30USD 1.93B55.7n/an/a
20212021-12-31USD 1.55B29.8n/an/a

Dividend history

Latest trailing dividend snapshot: annual dividend/share 8.13 USD, yield 29.4%.

About Supernus Pharmaceuticals Inc

Supernus, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company's core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sublingual film.

ETFs that hold Supernus Pharmaceuticals Inc

US-listed ETFs

Supernus Pharmaceuticals Inc is held by 107 US-listed ETFs, going by the latest portfolios they filed with the SEC. The 8 most traded of them:

ETFWeightFee
iShares Russell 2000 ETF (IWM)0.08%0.19%
Vanguard Morningstar Total Stock Market ETF (VTI)<0.01%0.03%
iShares Core S&P Small-Cap ETF (IJR)0.15%0.06%
Vanguard Total World Stock Index Fund ETF Shares (VT)<0.01%0.06%
Schwab U.S. Broad Market ETF (SCHB)<0.01%0.03%
iShares Core S&P Total U.S. Stock Market ETF (ITOT)<0.01%0.03%
Vanguard Russell 2000 Index Fund ETF Shares (VTWO)0.07%0.06%
iShares Russell 2000 Growth ETF (IWO)0.01%0.24%

Portfolios as filed with the SEC on Form N-PORT, dated May to July 2026. Brokers in the EU generally do not offer US-listed ETFs to retail investors.

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Supernus Pharmaceuticals Inc's market cap?

Supernus Pharmaceuticals Inc's market capitalization is USD 1.52B.

Does Supernus Pharmaceuticals Inc pay a dividend?

Supernus Pharmaceuticals Inc has a dividend yield of 29.4%.

What does Supernus Pharmaceuticals Inc do?

Supernus, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company's core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sublingual film.